- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Daniel J. Klein Explains How PAN Reduces Barriers to Care
The financial assistance the Patient Access Network (PAN) Foundation provides patients is an important part of the safety net and happens in a way that doesn't influence how patients get treatment or what products they use, explained Daniel J. Klein, president and CEO of PAN.
The financial assistance the Patient Access Network (PAN) Foundation provides patients is an important part of the safety net and happens in a way that doesn't influence how patients get treatment or what products they use, explained Daniel J. Klein, president and CEO of PAN.
Transcript (modified)
How does the Patient Access Network (PAN) reduce barriers to innovative care?
PAN is a charitable copay foundation. We operate under rules established by the Office of the Inspector General at HHS, and basically these rules are designed to ensure that there’s no inappropriate influence, coming from the people who donate to PAN, over the type of treatment that the patient receives. Most of our donations are from drug manufacturers and the OIG’s rules essentially require us to be agnostic about the treatments people can receive and get assistance with.
So when a manufacturer donates money to us we’re using that money to provide assistance for any of the treatments that a patient may need in a given disease area, which would include all of the generic medications, all of the other brand-name medications made by any manufacturers. We think that’s a unique and important part of the safety net, that within the rules that have been established by the OIG we’re able to provide assistance in a way that doesn’t influence how patients are getting their treatment or what products they’re using.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
